Aaron Mitchell, MD, MPH

Assistant Attending

Aaron Mitchell, MD, MPH

Assistant Attending
Aaron Mitchell, MD, MPH

Office Phone


Dr. Mitchell is an oncologist and health services researcher. He completed his clinical training at Duke University Hospital (Residency, internal medicine) and at University of North Carolina at Chapel Hill (Fellowship, medical oncology). He received an MPH in epidemiology from the University of North Carolina and completed a postdoctoral research fellowship at UNC’s Cecil G. Sheps Center for Health Services Research. His research interests are in understanding the interaction between financial incentives and physician behavior. He seeks to understand how changes to current reimbursement models for oncology services may be used to achieve better patient outcomes and reduce low-value care. 

His current projects include: 

1) Assessing the delivery of high-quality treatments across cancer types, measuring the frequency with which patients receive lower-quality treatments, and identifying the factors that determine whether patients receive high-quality or low-quality treatments; 

2) Measuring financial conflicts of interest among oncologists and the influence of these conflicts on clinical practice and guideline recommendations; 

3) Determining whether the profitability of different cancer drugs affects whether oncologists use them, and whether policy changes to how cancer drugs are reimbursed could improve outcomes and save money; and 

4) Improving the use of guideline-recommended supportive care medications for prostate cancer patients. 


His clinical interests are in genitourinary malignancies. He holds a co-appointment in the Genitourinary Oncology Service, treating patients with prostate cancer.


  1. Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, Diaz LA Jr, Korenstein D. Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review. Ann Intern Med. 2021 Mar;174(3):353-361. doi: 10.7326/M20-5665. Epub 2020 Nov 24. PMID: 33226858; PMCID: PMC8315858.
  2. Mitchell AP, Mishra Meza A, Panageas KS, Lipitz-Snyderman A, Bach PB, Morris MJ. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. J Natl Cancer Inst. 2022 Mar 8;114(3):419-426. doi: 10.1093/jnci/djab196. PMID: 34597380; PMCID: PMC8902329.
  3. Mitchell AP, Rotter JS, Patel E, Richardson D, Wheeler SB, Basch E, Goldstein DA. Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review. JAMA Oncol. 2019 Jun 1;5(6):893-899. doi: 10.1001/jamaoncol.2018.6196. PMID: 30605222; PMCID: PMC10309659.
  4. Mitchell AP, Basch EM, Dusetzina SB. Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncol. 2016 Dec 1;2(12):1628-1631. doi: 10.1001/jamaoncol.2016.2710. PMID: 27561170.
  5. Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med. 2018 Jun 1;178(6):854-856. doi: 10.1001/jamainternmed.2018.0776. PMID: 29630687; PMCID: PMC6145757.

View a full listing of Aaron Mitchell’s journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Aaron Mitchell discloses the following relationships and financial interests:

  • Institute for Clinical and Economic Review
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures